Neuronetics opened lower at $1.60, compared with its previous close of $1.62. In the last trading session, the stock traded between $1.39 and $1.61. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Neuronetics is now worth
$ 26.45
Resulting in a loss of
$ 73.55 (73.55%)
Note: Past profits do not guarantee future returns.
Rating from 2 Analysts
Today's Change
$-0.21 (-12.65%)
Day High
$1.61
Day Low
$1.39
Day Open
$1.60
Prev Close
$1.62
Volume
58,94,082
1W Return
-47.69%
1M Return
-33.72%
3M Return
-55.64%
6M Return
-5.98%
1Y Return
-35.68%
Market Cap ($ Mn)
110
PE Ratio
-
PB Ratio
12.53
PEG Ratio
-
ROE
-139.68%
ROCE
-28.08%
EPS (TTM)
$-0.02
1 Week
-47.69%
1 Month
-33.72%
3 Months
-55.64%
6 Months
-5.98%
9 Months
-21.39%
Neuronetics prices $30 million equity offering to ease debt covenants
Priced $30 million public offering at $1.60 per share. Proceeds intended for debt repayment and credit facility amendments. $15 million prepayment required by November 30, 2026 to avoid amendment termination.
YesterdayNeuronetics Q3FY26 Results: EPS beats estimate, revenue up 12.5% to $41.96M
Q3 EPS of $(0.02) beat consensus estimate of $(0.09) by 77.78%. Quarterly revenue of $41.962 million exceeded estimates by 3.80%. Full-year 2026 revenue guidance reaffirmed at $160 million to $164 million.
8 days agoNeuronetics integrates NeuroStar TMS with AdvancedMD EHR platform
Neuronetics integrates NeuroStar TMS with AdvancedMD EHR, the first such integration in the industry. Platform serves 65,000 practitioners across 13,000 independent practices. Integration aims to reduce administrative duplication in multi-session TMS care. Availability begins in Q4 for existing AdvancedMD users. NeuroStar has treated 253,000 patients with over 9.1 million sessions.
2mo agoNeuronetics and Chernett Announce Alignment Framework
Neuronetics, Inc. and second-largest shareholder Jorey Chernett established an alignment framework on Aug. 03, 2026, including board representation rights for Chernett. Largest shareholder Madryn Asset Management, LP reaffirmed its conviction in the company’s long-term value. The agreement reflects comfort with the balance sheet and confidence in management’s stewardship.
3mo agoNeuronetics grants RSUs to five new employees as inducement
Neuronetics, Inc. announced the granting of restricted stock units to five new non-executive employees under Nasdaq Listing Rule 5635(c)(4). The awards, approved by the Compensation Committee, vest over three to four years subject to continued employment. This move supports the company's growth in interventional mental health via its NeuroStar TMS technology and Greenbrook clinic network.
3mo agoNeuronetics appoints Nir Naor CFO, announces management changes
Neuronetics, Inc. has appointed Nir Naor as Chief Financial Officer effective July 23, 2026, bringing over 20 years of experience. The company also promoted Cory Anderson to Executive Vice President and General Manager of Greenbrook effective July 1, 2026, and announced that Andrew Macan will step down as Executive Vice President, Chief Legal Officer and Corporate Secretary effective August 15, 2026.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $109.29 | -1.06% | $1,89,283.94M | 36.28 | |
| $449.53 | -0.11% | $1,55,826.88M | 42.73 | |
| $101.61 | +0.02% | $1,29,976.46M | 24.46 | |
| $318.79 | -1.70% | $1,21,360.48M | 34.27 | |
| $45.13 | +0.96% | $65,414.72M | 18.96 | |
| $105.81 | +1.73% | $60,840.75M | 53.70 | |
| $214.52 | +0.90% | $58,432.46M | 44.07 | |
| $82.60 | -1.26% | $37,346.60M | 16.49 | |
| $42.16 | +3.06% | $37,044.18M | 89.05 | |
| $72.46 | -2.16% | $35,027.16M | 54.55 | |
| $237.20 | +1.61% | $33,458.08M | 23.04 | |
| $80.35 | +0.53% | $29,964.75M | 36.04 |
An investment of $100 made 5 years ago in Neuronetics is now worth
$ 26.45
Resulting in a loss of
$ 73.55 (73.55%)
Note: Past profits do not guarantee future returns.
